| ID | Sequence | Length | GC content |
|---|---|---|---|
| CUUUCCCUGGUGUGAUUCCGUCCUGCGCGGUUGUUCUCUGGAGCAGCGU… | 1600 nt | 0.3956 | |
| GGGCGAUGUCCUUGCUAAUUUGGAGACUGAUUCAGUCCCCUUUUGGCCC… | 1355 nt | 0.4081 | |
| CUUUCCCUGGUGUGAUUCCGUCCUGCGCGGUUGUUCUCUGGAGCAGCGU… | 1240 nt | 0.4161 | |
| CUUUCCCUGGUGUGAUUCCGUCCUGCGCGGUUGUUCUCUGGAGCAGCGU… | 1513 nt | 0.3979 | |
| CUUUCCCUGGUGUGAUUCCGUCCUGCGCGGUUGUUCUCUGGAGCAGCGU… | 939 nt | 0.4121 | |
| CUUUCCCUGGUGUGAUUCCGUCCUGCGCGGUUGUUCUCUGGAGCAGCGU… | 1320 nt | 0.4129 | |
| CUUUCCCUGGUGUGAUUCCGUCCUGCGCGGUUGUUCUCUGGAGCAGCGU… | 1233 nt | 0.4169 |
The protein encoded by this gene is involved in several cellular processes, including centrosome duplication, protein chaperoning, and cell proliferation. The encoded phosphoprotein shuttles between the nucleolus, nucleus, and cytoplasm, chaperoning ribosomal proteins and core histones from the nucleus to the cytoplasm. This protein is also known to sequester the tumor suppressor ARF in the nucleolus, protecting it from degradation until it is needed. Mutations in this gene are associated with acute myeloid leukemia. Dozens of pseudogenes of this gene have been identified. [provided by RefSeq, Aug 2017] CIViC Summary for NPM1 Gene AML with mutated NPM1 is a provisional entity in the WHO classification of AML and is recommended to be tested in patients with cytogenetically normal AML (CN-AML). FLT3 mutations should be evaluated concurrently as they have prognostic consequences. NPM1 mutations are concentrated in exon 12, most frequently W288fs which results in cytoplasmic sequestration of the protein. Exon 12 NPM1 mutations in the absence of FLT3-ITD are associated with good prognostic outcomes. Mice expressing the Npm1-W288fs mutation develop myeloproliferative neoplasms but not overt leukemia, indicating it may require additional mutations to promote leukemic development.
No relevant information is available at the moment.